# Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

> **NCT05971758** · PHASE2 · RECRUITING · sponsor: **University of California, Los Angeles** · enrollment: 20 (estimated)

## Conditions studied

- Cushing Disease

## Interventions

- **DRUG:** Fimepinostat

## Key facts

- **NCT ID:** NCT05971758
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05971758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05971758, "Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05971758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*